Microfluidics Market 2022 Industry Growth, Top Key Players, Segmentation and Forecast till 2030

According to Nova one advisor, the global Microfluidics market size is evaluated at USD 23.65 billion in 2022 and is expected to hit around USD 72.09 billion by 2030, growing at a CAGR of 12.40% from 2022 to 2030. 

Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7556

 Key Takeaways:

• By technology, the medical segment upheld the largest share of the market in 2021 and is expected to grow at a CAGR of 12.55% in the forecast period. Microfluidics contributes significantly to medical applications of biological analysis, chemical synthesis, and information technology
• The PCR & RT-PCR segment is expected to grow lucratively at 14.99% in the forecast period. The application of microfluidics in PCR has been significant in recent years as it enables the whole biological process to be integrated resulting in multiplexed, high-throughput, and highly parallel assays
• By material, the polydimethylsiloxane (PDMS) segment is anticipated to grow at the fastest CAGR of 13.60% during the forecast period. The material offers several advantages such as biocompatibility, permeability, and low levels of autofluorescence, which broaden its applications in biotechnology and biomedical engineering
• Based on application, the lab-on-a-chip segment upheld the largest market share in 2021 and is projected to grow at a CAGR of 11.08% in the forecast period. This is due to its increasing adoption in medical settings focusing on human diagnostics, and DNA analysis
• Furthermore, the lab-on-a-chip offers high detection speed, and consistent sensitivity during amplification and detection procedures for DNA and RNA molecules. In addition, as lab-on-a-chip enables rapid sequencing of DNA probes, the segment is projected to dominate the market in the forecast period
• North America dominated the global market in 2021 and is projected to reveal a CAGR of 10.77% in the forecast period. The presence of key players and growth in research funding from government organizations and industries is likely to continue driving the region’s market during the forecast period
• Asia Pacific is expected to be the fastest-growing market with a CAGR of 15.81% in the forecast period. This growth is attributed to sophisticated research infrastructure, a developing economy, and affordable labor

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/7556

Report Scope of the Microfluidics Market

The demand for microfluidics-based devices is expected to increase due to the introduction of improved technology such as digital microfluidics, which enables on-chip biochemical analysis. An increase in research activities undertaken by analytical and clinical researchers have also driven the demand for microfluidics device. For instance, in May 2022, a research team from the University of Minnesota developed an innovative microfluidic chip for disease diagnosing that uses a minimum number of components and can be operated wirelessly by a smartphone.

Miniature microfluidic-based tools are gaining significant popularity among consumers, which has encouraged companies to invest in their development. Since microfluidics is the underlying principle of lab-on-a-chip devices, it offers various benefits such as minimal sample volume, minimal reagent usage, reduced waste, and rapid processing. Fully automated microfluidics with enhanced functional capabilities, and robust modularity are creating growth opportunities for manufacturers operating in the market. This can be attributed to the fact that modular chips can interface with several instruments. In addition, companies operating in the field of drug discovery are striving to minimize overhead costs and timelines to offset the estimated decline in revenue owing to a significant number of drugs going off-patent.

The implementation of microfluidics is expanding in the field of diagnostics, especially in POC diagnostics. This is also supplemented by microfluidics-integrated biosensor technologies that are expected to enhance POC diagnostics. The combination of microfluidic components with POC devices is largely focused on achieving sensitivity, stability, accuracy, affordability, and obtaining minimally invasive POC technology. Microfluidic POC technologies are expected to enhance patient care by ensuring personalization, early disease detection, and easy monitoring.

In addition, COVID-19 has further upscaled the use of microfluidics. Point-of-care testing involves small equipment, regulates the process, and has limited testing cycles. This allows single or multiple research laboratory services to evaluate biological samples and diagnose harmful diseases simultaneously. In general, stage assessment and rapid detection of viral epidemics are vital to overcoming pandemic situations and diagnosing rapidly. Therefore, combining microfluidic devices with point-of-care testing enhances detection efficiency. At the same time, point-of-care testing of microfluidic chips enhances user accessibility, improves sensitivity and accuracy, and reduces the detection time, all of which are advantageous in detecting SARS-CoV-2.

Further, several acquisitions in the microfluidics industry are aimed at enhancing technologies for expanding the scope of microfluidics-related applications. In June 2021, Danaher Corporation announced that Precision NanoSystems (PNI), a Canada-based solution provider, was acquired by its life science business. PNI offered proprietary genetic toolkit platforms, including LNP delivery and nanoparticle manufacturing via the microfluidic-based platform, which further complemented the company’s portfolio of life science products.

On the other hand, high operational costs hinder the microfluidics market growth to a certain extent. The fabrication of microfluidics chips has certain issues such as open channel construction that require bonding of machine parts to form a final enclosed structure. The open channel is formed by the etching of glass or silicon. This step is slow, costly, and requires the use of aggressive chemicals. In addition, most of the microfluidic prototyping methods are not compatible with the batch process, and are also complicated and costly.

Regional Insights

North America dominated the microfluidics market with a share of 43.22% in 2021 and is projected to exhibit a CAGR of 10.77% during the forecast period. An increase in research funding from government organizations and industries is the major factor driving the market growth. The demand for microfluidics devices in the research and diagnostics field has propelled the industry-academia collaboration to accelerate the commercialization of lab-built devices.

For instance, in July 2020, Fluidigm Corporation executed a letter contract with the National Institute of Biomedical Imaging and Bioengineering, and the National Institutes of Health for the Rapid Acceleration of Diagnostics program. The venture, with an overall proposed budget of up to USD 37 million, intended to expand the output capabilities and production capacity for COVID-19 testing with microfluidics technology from Fluidigm. In addition, the program fast-tracked commercialization and development of groundbreaking technologies to significantly increase testing capacity for SARS-CoV-2 in the U.S.

Asia Pacific is expected to expand at a high growth rate of 15.81% during the forecast period owing to sophisticated research infrastructure, a developing economy, and affordable labor. International players are keen on investing in the untapped APAC microfluidics market. The market for diagnostic tests based on microfluidic is majorly dominated by foreign players. However, key players in the region are proposing innovative and interesting solutions in terms of performance, and more significantly in terms of price, which can allow them to boost their market share in the coming years.

The government in China has set up a strategic plan to broadly enhance the local industry and make the country an important player. This plan, named Made in China 2025, incorporates a focus on medical devices and pharmaceuticals. As a vital tool for life sciences and diagnostics applications, microfluidic technology is expected to benefit the money spent in the perspective of this strategic plan.

Some of the prominent players in the Microfluidics Market include:

• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• PerkinElmer, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Abbott
• Thermo Fisher Scientific
• Standard BioTools

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Microfluidics market

• Technology
  • Medical/Healthcare
    • PCR & RT-PCR
    • Gel Electrophoresis
    • Microarrays
    • ELISA
    • Others
  • Non-medical
• Material
  • Silicon
  • Glass
  • Polymer
  • PDMS
  • Others
• Application
  • Lab-on-a-chip
    • Medical
    • Non-Medical
  • Organs-on-chips
    • Medical
    • Non-Medical
  • Continuous Flow Microfluidics
    • Medical
    • Non-Medical
  • Optofluidics And Microfluidics
    • Medical
    • Non-Medical
  • Acoustofluidics And Microfluidics
    • Medical
    • Non-Medical
  • Electrophoresis And Microfluidics
    • Medical
    • Non-Medical

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7556

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/